Lapatinib versus Lapatinib plus Capecitabine as secondline treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Lorenzen, S. and Helbig, U. and Knorrenschild, Riera J. and Haag, G. M. and Pohl, M. and Thuss-Patience, P. and Bassermann, F. and Weissinger, F. and Schnoy, E. and Becker, K. and Rueschoff, J. and Eisenmenger, A. and Karapanagiotou-Schenkel, I and Lordick, F. (2014) Lapatinib versus Lapatinib plus Capecitabine as secondline treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ONCOLOGY RESEARCH AND TREATMENT, 37 (Suppl5). p. 121. ISSN 2296-5270, 2296-5262

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Petra Gürster
Date Deposited: 07 Aug 2020 05:39
Last Modified: 07 Aug 2020 05:39
URI: https://pred.uni-regensburg.de/id/eprint/9416

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.